ORLANDO, Fla. (AP) – Biopharmaceutical company Immunomedics Inc. said its drug candidate epratuzumab succeeded in a midstage clinical trial focusing on a type of cancer called follicular lymphoma.
Follicular lymphoma is the most common type of non-Hodgkin lymphoma, which is a cancer affecting the lymph system. The drug candidate, in combination with Roche AG and Biogen Idec Inc.’s Rituxan, was successful in prompting a response in patients. The results are from 57 evaluable patients who have not received prior treatment for the cancer.
Date: December 7, 2010
Source: Associated Press